IRCT20220211053992N13招募中Unknown
In vivo bioequivalence study of Citalopram 40 mg tablet of Hakim pharmaceutical Co. compared to innovator product
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 59 years（—）
- 性别
- All
入选标准
- •General Health (in terms of Liver, Heart and Kidney)
- •Age (18-59 years old)
排除标准
- •History of cardiovascular, liver and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
研究者
相似试验
已完成
Unknown
Bioequivalence Study of Citalopram 40 mg manufactured by Shafa Pharmaceutical and Celexa manufactured by LundbeckIRCT20220209053979N11Shafa Pharmaceutical Company24
招募中
2 期
A comparative study of the effect of citalopram in the prevention of delirium in intubated patients without brain damage in Labafinejad Hospital ICIRCT20190215042716N6Shahid Beheshti University of Medical Sciences62
招募中
3 期
Effect of Citalopram on EndometriosisEndometriosisIRCT20180211038692N2Tehran University of Medical Sciences80
招募中
不适用
In-vivo Bioequivalence Test of Ticagrelor® tablet with brand drugs (BRILINTA® AstraZeneca UK).IRCT20200105046010N31ABIDI Pharmaceutical Company24
尚未招募
不适用
In vivo Bioequivalence study of Ticagrelor TabletIn the present study, no diseases will be examined and products will be administered by healthy volunteers..IRCT20210519051345N1Tabriz University of Medical Sciences24